Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

p38 MAPK and NF-κB Survival Pathways As Targets for Action of Rituximab In Vivo in a Xenographic Model,

Gabriel G Vega, PhD, Monica Arteaga-Campos, Bch, Melisa Martinez-Paniagua, PhD, Natividad Neri Munoz, PhD MD, M. J Nambo, Isabel Alvarado, Ivonne Cuadra, MD, Sara Huerta-Yepez, PhD, Mario Vega, PhD

Blood (2017) 130 (Supplement 1): 5199.

https://doi.org/10.1182/blood.V130.Suppl_1.5199.5199

Published: 2017

Journal Articles

Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL

Mario I Vega, PhD, Alejandro Aviles-Salas, MD, J Ramon Chalapud, MD, Sara Huerta-Yepez, PhD, Rogelio Hernandez-Pando, MD, PhD, Melisa Martinez-Paniagua, BSc, MSc, Bernardo Martinez-Miguel, BCh, Miriam Hernandez-Atenogenes, ChB, Gabriel G Vega, MDVZ, Haiming Chen, James R. Berenson, MD, Hector Mayani, PhD, Otoniel Martinez-Maza, PhD, Benjamin Bonavida, Ph.D

Blood (2011) 118 (21): 2647.

https://doi.org/10.1182/blood.V118.21.2647.2647

Published: 2011

Journal Articles

An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Melisa Martinez-Paniagua, BSc, MSc, Stavroula Baritaki, PhD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 4919.

https://doi.org/10.1182/blood.V116.21.4919.4919

Published: 2010

Journal Articles

Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Melisa Martinez-Paniagua, BSc, MSc, Stavroula Baritaki, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 4931.

https://doi.org/10.1182/blood.V116.21.4931.4931

Published: 2010

Journal Articles

The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bcl xl ) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy

Melisa Martinez-Paniagua, BSc, MSc, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Hari Hariharan, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 2887.

https://doi.org/10.1182/blood.V116.21.2887.2887

Published: 2010

Journal Articles

Upregulation of Krüppel-Like Factor 4 (KLF-4) Expression as a Potential Tumor Progression Gene Product in Non-Hodgkin's Lymphoma.

Mario I. Vega, PhD, Juan vazquez-Islas, Melisa Martinez-Paniagua, Miriam Hernandez-Atenogenes, Bernardo martinez-Miguel, Altagracia Maldonado-Valenzuela, B.Sc., Cesar Gonzalez-Bonilla, Sara Huerta-Yepez, PhD., Otoniel Martinez-Maza, Ph.D., Benjamin Bonavida, PhD

Blood (2009) 114 (22): 5022.

https://doi.org/10.1182/blood.V114.22.5022.5022

Published: 2009

Journal Articles

Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization

Mario I Vega, Ph.D., Melisa Martinez-Paniagua, Sara Huerta-Yepez, PhD., Benjamin Bonavida, PhD

Blood (2008) 112 (11): 2613.

https://doi.org/10.1182/blood.V112.11.2613.2613

Published: 2008

Journal Articles

Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF-Kb Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance

Melisa Martinez-Paniagua, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD., Stavroula Baritaki, James R. Berenson, MD, Haris Hariharan, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 3623.

https://doi.org/10.1182/blood.V112.11.3623.3623

Published: 2008

Journal Articles

Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1.

Mario I. Vega, PhD, Melisa Martinez-Paniagua, Sara Huerta-Yepez, PhD., Yeung Kam, Stavroula Baritaki, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 1596.

https://doi.org/10.1182/blood.V112.11.1596.1596

Published: 2008

Journal Articles

Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance

Stavroula Baritaki, PhD, Jose Rodriguez, Gustavo Helguera, PhD, Melisa Martinez-Paniagua, Mario Vega, PhD, Sara Huerta-Yepez, PhD., Ali Jazirehi, PhD, Demetrios Spandidos, PhD, Manuel L Penichet, M.D., Ph.D., Benjamin Bonavida, PhD

Blood (2008) 112 (11): 3770.

https://doi.org/10.1182/blood.V112.11.3770.3770

Published: 2008

Journal Articles

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mario I. Vega, PhD, Melisa Martinez- Paniagua, Sara Huerta-Yepez, PhD., Eriko Suzuki, Kazuo Umezawa, Kam Yeung, Ph.D., Massimo Libra, Stavroula Baritaki, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4973.

https://doi.org/10.1182/blood.V112.11.4973.4973

Published: 2008

Journal Articles

Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1)

Melisa Martinez- Paniagua, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Bonilla Gonzalez, PhD, Vanessa Suarez, Stavroula Baritaki, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4976.

https://doi.org/10.1182/blood.V112.11.4976.4976

Published: 2008

NARROW

p38 MAPK and NF-κB Survival Pathways As Targets for Action of Rituximab In Vivo in a Xenographic Model,

Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL

An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells

Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab

The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bcl xl ) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy

Upregulation of Krüppel-Like Factor 4 (KLF-4) Expression as a Potential Tumor Progression Gene Product in Non-Hodgkin's Lymphoma.

Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization

Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF-Kb Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance

Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1.

Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only